On August 14, JD HEALTH rose 5.11% in regular trading, trading at HK$41.72/share, with turnover of HK$129 million. The rally follows the company's release of robust first-half results the previous day.

JD HEALTH reported H1 revenue of RMB 40.9 billion, up 15.9% year over year, while attributable profit climbed 32.4% to RMB 3.44 billion. Earnings per share rose to RMB 1.08 from RMB 0.81 in the prior-year period. Non-IFRS operating profit reached RMB 3.5 billion, surging 40.3% year over year, reflecting significant margin expansion as gross margin improved from 25.2% to 26.1%. The company also highlighted its first-mover launch of 65 new drugs in H1, covering oncology, dermatology, and chronic disease segments, reinforcing its position as the largest online pharmaceutical retail platform in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)